Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Reyataz
REYATAZ 200 mg hard capsules REYATAZ 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 15–16
HOS-112086 · Präparat HOS-093615
15
Medicinal products by Interaction Recommendations concerning co-
therapeutic area administration
ACID REDUCING AGENTS
H2-Receptor antagonists
Without Tenofovir
In HIV-infected patients with atazanavir/ritonavir at the recommended For patients not taking tenofovir,
dose 300/100 mg once daily if REYATAZ 300 mg/ritonavir
Famotidine 20 mg twice daily Atazanavir AUC: ↓18% (↓25% ↑1%) 100 mg and H2-receptor antagonists
Atazanavir Cmax: ↓20% (↓32% ↓7%) are co-administered, a dose
Atazanavir Cmin: ↔1% (↓16% ↑18%) equivalent to famotidine 20 mg
twice daily should not be exceeded.
Famotidine 40 mg twice daily Atazanavir AUC: ↓23% (↓32% ↓14%) If a higher dose of an H2-receptor
Atazanavir Cmax: ↓23% (↓33% ↓12%) antagonist is required (e.g.,
Atazanavir Cmin: ↓20% (↓31% ↓8%) famotidine 40 mg twice daily or
In healthy volunteers with atazanavir/ritonavir at an increased dose equivalent) an increase of the
of 400/100 mg once daily REYATAZ/ritonavir dose from
Famotidine 40 mg twice daily Atazanavir AUC: ↔3% (↓14% ↑22%) 300/100 mg to 400/100 mg can be
Atazanavir Cmax: ↔2% (↓13% ↑8%) considered.
Atazanavir Cmin: ↓14% (↓32% ↑8%)
With Tenofovir disoproxil fumarate 300 mg once daily (equivalent to 245 mg tenofovir disoproxil)
In HIV-infected patients with atazanavir/ritonavir at the recommended dose For patients who are taking
of 300/100 mg once daily tenofovir disoproxil fumarate, if
Famotidine 20 mg twice daily Atazanavir AUC: ↓21% (↓34% ↓4%)* REYATAZ/ritonavir with both
Atazanavir Cmax: ↓21% (↓36% ↓4%)* tenofovir disoproxil fumarate and
Atazanavir Cmin: ↓19% (↓37% ↑5%)* an H2-receptor antagonist are co-
administered, a dose increase of
Famotidine 40 mg twice daily Atazanavir AUC: ↓24% (↓36% ↓11%)* REYATAZ to 400 mg with 100 mg
Atazanavir Cmax: ↓23% (↓36% ↓8%)* of ritonavir is recommended. A
Atazanavir Cmin: ↓25% (↓47% ↑7%)* dose equivalent to famotidine
In HIV-infected patients with atazanavir/ritonavir at an increased dose 40 mg twice daily should not be
of 400/100 mg once daily exceeded.
Famotidine 20 mg twice daily Atazanavir AUC: ↑18% (↑6.5% ↑30%)*
Atazanavir Cmax: ↑18% (↑6.7% ↑31%)*
Atazanavir Cmin: ↑24% (↑10% ↑39%)*
Famotidine 40 mg twice daily Atazanavir AUC: ↔2.3% (↓13% ↑10%)*
Atazanavir Cmax: ↔5% (↓17% ↑8.4%)*
Atazanavir Cmin: ↔1.3% (↓10% ↑15)*
*When compared to atazanavir 300 mg
once daily with ritonavir 100 mg once
daily and tenofovir disoproxil fumarate
300 mg all as a single dose with food.
When compared to atazanavir 300 mg with
ritonavir 100 mg without tenofovir
disoproxil fumarate, atazanavir
concentrations are expected to be
additionally decreased by about 20%.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) famotidine (HOS-112087) tenofovir disoproxil (HOS-108843) fumarate (HOS-108845) tenofovir disoproxil fumarate (HOS-110471) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage 695cfffb4426adfdcee429184e2620b1c5bb6af71aadbc31f5b2433e0455e449 · Zeichen 31489–35584 im Abschnitt
Wechselwirkungen · Reyataz
REYATAZ 200 mg hard capsules REYATAZ 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 24–25
HOS-112119 · Präparat HOS-093615
24
In case of withdrawal of ritonavir from the recommended atazanavir-boosted regimen
(see section 4.4)
The same recommendations for drug interactions would apply except:
that co-administration is not recommended with tenofovir, proton pump inhibitors, and
buprenorphine and contraindicated with carbamazepine, phenytoin and phenobarbital.
that co-administration with famotidine is not recommended but if required, atazanavir without
ritonavir should be administered either 2 hours after famotidine or 12 hours before. No single
dose of famotidine should exceed 20 mg, and the total daily dose of famotidine should not
exceed 40 mg.
the need to consider that:
co-administration of apixaban, dabigatran, or rivaroxaban and REYATAZ without
ritonavir may affect apixaban, dabigatran, or rivaroxaban concentrations
co-administration of voriconazole and REYATAZ without ritonavir may affect atazanavir
concentrations
co-administration of fluticasone and REYATAZ without ritonavir may increase
fluticasone concentrations relative to fluticasone given alone
if an oral contraceptive is administered with REYATAZ without ritonavir, it is
recommended that the oral contraceptive contain no more than 30 μg of ethinyloestradiol
no dose adjustment of lamotrigine is required
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) lamotrigine (HOS-086242) fluticasone (HOS-108914) phenobarbital (HOS-085617) carbamazepine (HOS-085618) famotidine (HOS-112087) dabigatran (HOS-112096) buprenorphine (HOS-086193) rivaroxaban (HOS-086236) voriconazole (HOS-084524) apixaban (HOS-112091) ritonavir (HOS-084521) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage e782985711b73a21e78ab499d92e8fece89fe8ca127ddbacf1a99dce682dcc07 · Zeichen 75495–76934 im Abschnitt
Wechselwirkungen · Reyataz
REYATAZ 50 mg oral powder · Abschnitt 4.5 · PDF-Seite 50–51
HOS-112181 · Präparat HOS-093615
50
Medicinal products by Interaction Recommendations
therapeutic area concerning co-administration
Rifampicin Rifampicin is a strong CYP3A4 inducer The combination of rifampicin
and has been shown to cause a 72% and REYATAZ is
decrease in atazanavir AUC which can contraindicated (see
result in virological failure and resistance section 4.3).
development. During attempts to overcome
the decreased exposure by increasing the
dose of REYATAZ or other protease
inhibitors with ritonavir, a high frequency
of liver reactions was seen.
ANTIPSYCHOTICS
Quetiapine Due to CYP3A4 inhibition by REYATAZ, Co-administration of
concentrations of quetiapine are expected quetiapine with REYATAZ is
to increase. contraindicated as REYATAZ
may increase quetiapine-
related toxicity. Increased
plasma concentrations of
quetiapine may lead to coma
(see section 4.3).
Lurasidone REYATAZ is expected to increase plasma Co-administration of
levels of lurasidone due to CYP3A4 lurasidone with REYATAZ is
inhibition. contraindicated as this may
increase lurasidone-related
toxicity (see section 4.3).
ACID REDUCING AGENTS
H2-Receptor antagonists
Without Tenofovir
In HIV-infected patients with atazanavir/ritonavir at the recommended For patients not taking
dose 300/100 mg once daily tenofovir, if REYATAZ
Famotidine 20 mg twice daily Atazanavir AUC: ↓18% (↓25% ↑1%) 300 mg/ritonavir 100 mg and
Atazanavir Cmax: ↓20% (↓32% ↓7%) H2-receptor antagonists are co-
Atazanavir Cmin: ↔1% (↓16% ↑18%) administered, a dose equivalent
to famotidine 20 mg twice
Famotidine 40 mg twice daily Atazanavir AUC: ↓23% (↓32% ↓14%) daily should not be exceeded.
Atazanavir Cmax: ↓23% (↓33% ↓12%) If a higher dose of an H2-
Atazanavir Cmin: ↓20% (↓31% ↓8%) receptor antagonist is required
In healthy volunteers with atazanavir/ritonavir at an increased dose (e.g., famotidine 40 mg twice
of 400/100 mg once daily daily or equivalent) an increase
Famotidine 40 mg twice daily Atazanavir AUC: ↔3% (↓14% ↑22%) of the REYATAZ/ritonavir
Atazanavir Cmax: ↔2% (↓13% ↑8%) dose from 300/100 mg to
Atazanavir Cmin: ↓14% (↓32% ↑8%) 400/100 mg can be considered.
With Tenofovir disoproxil fumarate 300 mg once daily (equivalent to 245 mg tenofovir disoproxil)
In HIV-infected patients with atazanavir/ritonavir at the recommended dose For patients who are taking
of 300/100 mg once daily tenofovir disoproxil
Famotidine 20 mg twice daily Atazanavir AUC: ↓21% (↓34% ↓4%)* fumarate, if
Atazanavir Cmax: ↓21% (↓36% ↓4%)* REYATAZ/ritonavir with both
Atazanavir Cmin: ↓19% (↓37% ↑5%)* tenofovir disoproxil fumarate
and an H2-receptor antagonist
Famotidine 40 mg twice daily Atazanavir AUC: ↓24% (↓36% ↓11%)* are co-administered, a dose
Atazanavir Cmax: ↓23% (↓36% ↓8%)* increase of REYATAZ to
Atazanavir Cmin: ↓25% (↓47% ↑7%)* 400 mg with 100 mg of
In HIV-infected patients with atazanavir/ritonavir at an increased dose ritonavir is recommended. A
of 400/100 mg once daily dose equivalent to famotidine
Famotidine 20 mg twice daily Atazanavir AUC: ↑18% (↑6.5% ↑30%)* 40 mg twice daily should not
Atazanavir Cmax: ↑18% (↑6.7% ↑31%)* be exceeded.
Atazanavir Cmin: ↑24% (↑10% ↑39%)*
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) quetiapine (HOS-086150) protease (HOS-085623) famotidine (HOS-112087) tenofovir disoproxil (HOS-108843) lead (HOS-085592) fumarate (HOS-108845) tenofovir disoproxil fumarate (HOS-110471) ritonavir (HOS-084521) lurasidone (HOS-086148)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage d69eeb45d796d1cd8f98e48958156005dc8ba777a37e1a215ebb755a767192dc · Zeichen 30340–35663 im Abschnitt
Wechselwirkungen · Reyataz
REYATAZ 50 mg oral powder · Abschnitt 4.5 · PDF-Seite 51–52
HOS-112182 · Präparat HOS-093615
51
Medicinal products by Interaction Recommendations
therapeutic area concerning co-administration
Famotidine 40 mg twice daily Atazanavir AUC: ↔2.3% (↓13% ↑10%)*
Atazanavir Cmax: ↔5% (↓17% ↑8.4%)*
Atazanavir Cmin: ↔1.3% (↓10% ↑15)*
*When compared to atazanavir 300 mg
once daily with ritonavir 100 mg once daily
and tenofovir disoproxil fumarate 300 mg
all as a single dose with food. When
compared to atazanavir 300 mg with
ritonavir 100 mg without tenofovir
disoproxil fumarate,, atazanavir
concentrations are expected to be
additionally decreased by about 20%.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) famotidine (HOS-112087) fumarate (HOS-108845) tenofovir disoproxil fumarate (HOS-110471) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage 2052af8108a80318b3cccb01a97ff4ba8440a5a6e22ac83aa15556f86a729697 · Zeichen 35722–36749 im Abschnitt
Wechselwirkungen · Yentreve
YENTREVE 20 mg hard gastro-resistant capsules YENTREVE 40 mg hard gastro-resistant capsules · Abschnitt 4.5 · PDF-Seite 7
HOS-112880 · Präparat HOS-093777
Effects of other medicinal products on duloxetine
Antacids and H2 antagonists: Co-administration of YENTREVE with aluminium- and magnesium-
containing antacids or with famotidine had no significant effect on the rate or extent of duloxetine
absorption after administration of a 40 mg oral dose.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): famotidine (HOS-112087)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-09T15:33:00Z · SHA-256 d927c7a519b8bbcba3c7ad828fbbce3643ea8a3886fcc0403d91cbec6695f99d · Passage 2456654e7552a902e2549ce4bd9a26483689745ead1da7d56d7090a8f2d42526 · Zeichen 3862–4156 im Abschnitt
Wechselwirkungen · Cymbalta
Cymbalta 30 mg hard gastro-resistant capsules Cymbalta 60 mg hard gastro-resistant capsules · Abschnitt 4.5 · PDF-Seite 8
HOS-113280 · Präparat HOS-093901
Effects of other medicinal products on duloxetine
Antacids and H2 antagonists: Co-administration of duloxetine with aluminium- and magnesium-
containing antacids or duloxetine with famotidine had no significant effect on the rate or extent of
duloxetine absorption after administration of a 40 mg oral dose.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): famotidine (HOS-112087)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-09T15:40:00Z · SHA-256 a3b2a486f9b4069e76d38032cad9e45c893ee290991d9c0e8b3ea325ef1c101c · Passage ab76508516ee784b09479ba48bcff5f53430c87d6abf98651a0e434a77f1f025 · Zeichen 4048–4355 im Abschnitt
Wechselwirkungen · Sprycel
SPRYCEL 20 mg film-coated tablets SPRYCEL 50 mg film-coated tablets SPRYCEL 70 mg film-coated tablets SPRYCEL 80 mg film-coated tablets SPRYCEL 100 mg film-coated tablets SPRYCEL 140 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 11
HOS-116685 · Präparat HOS-094467
Histamine-2 antagonists and proton pump inhibitors
Long-term suppression of gastric acid secretion by H2 antagonists or proton pump inhibitors (e.g.
famotidine and omeprazole) is likely to reduce dasatinib exposure. In a single-dose study in healthy
subjects, the administration of famotidine 10 hours prior to a single dose of SPRYCEL reduced
dasatinib exposure by 61%. In a study of 14 healthy subjects, administration of a single 100-mg dose
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): famotidine (HOS-112087) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-02T12:05:00Z · SHA-256 c065657005bf3f51d58db1cb5b29a1453d36e1fc897c0adb5e47ed684f07722e · Passage d2afa3fdf1bf0658557d2b5fa1b3cf6262d393daa417a1e89661e9fbd0270118 · Zeichen 1809–2253 im Abschnitt
Wechselwirkungen · Sprycel
SPRYCEL 10 mg/mL powder for oral suspension · Abschnitt 4.5 · PDF-Seite 47
HOS-116739 · Präparat HOS-094467
Histamine-2 antagonists and proton pump inhibitors
Long-term suppression of gastric acid secretion by H2 antagonists or proton pump inhibitors (e.g.
famotidine and omeprazole) is likely to reduce dasatinib exposure. In a single-dose study in healthy
subjects, the administration of famotidine 10 hours prior to a single dose of SPRYCEL reduced
dasatinib exposure by 61%. In a study of 14 healthy subjects, administration of a single 100-mg dose
of SPRYCEL 22 hours following a 4-day, 40-mg omeprazole dose at steady state reduced the AUC of
dasatinib by 43% and the Cmax of dasatinib by 42%. The use of antacids should be considered in place
of H2 antagonists or proton pump inhibitors in patients receiving SPRYCEL therapy (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): famotidine (HOS-112087) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-02T12:05:00Z · SHA-256 c065657005bf3f51d58db1cb5b29a1453d36e1fc897c0adb5e47ed684f07722e · Passage 81210217abe1aa9b5fe84545a2638c76205c7db3f3be6c57c518505b88d5dc45 · Zeichen 1809–2551 im Abschnitt
Wechselwirkungen · Tasigna
Tasigna 50 mg hard capsules Tasigna 150 mg hard capsules Tasigna 200 mg hard capsules · Abschnitt 4.5 · PDF-Seite 11
HOS-118208 · Präparat HOS-094783
In a study in healthy subjects, no significant change in nilotinib pharmacokinetics was observed when
a single 400 mg dose of nilotinib was administered 10 hours after and 2 hours before famotidine.
Therefore, when the concurrent use of a H2 blocker is necessary, it may be administered
approximately 10 hours before and approximately 2 hours after the dose of Tasigna.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): famotidine (HOS-112087)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-17T17:21:00Z · SHA-256 efb2ca2c5c7d9a0e740759217e71ff7f08cf3763f8c41f5c02f5d10733d67b3a · Passage d3303fad32d5a04bff37b02713aca97db0cd15b2f65ad86d95f04bec29db78ff · Zeichen 2522–2891 im Abschnitt
Wechselwirkungen · Isentress
ISENTRESS 400 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-119065 · Präparat HOS-094905
Co-administration of raltegravir with other agents that increase gastric pH (e.g., omeprazole and
famotidine) may increase the rate of raltegravir absorption and result in increased plasma levels of
raltegravir (see Table 1). Safety profiles in the subgroup of patients in Phase III trials taking proton
pump inhibitors or H2 antagonists were comparable with those who were not taking these antacids.
Therefore, no dose adjustment is required with use of proton pump inhibitors or H2 antagonists.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): famotidine (HOS-112087) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-17T13:16:00Z · SHA-256 6b95e5ffe7a0fcf11532bc18fa0933606a4dfe39d9d876e4b916acb6d89e55cc · Passage 58c95c26ef8b07dab80595f47ddccd1a03de32f424e472ba71faed56abb23dc3 · Zeichen 3917–4413 im Abschnitt
Wechselwirkungen · Isentress
ISENTRESS 400 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9
HOS-119088 · Präparat HOS-094905
famotidine raltegravir AUC ↑ 44 % No dose adjustment required
(raltegravir 400 mg Twice Daily) raltegravir C12 hr ↑ 6 % for raltegravir.
raltegravir Cmax ↑ 60 %
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): famotidine (HOS-112087)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-17T13:16:00Z · SHA-256 6b95e5ffe7a0fcf11532bc18fa0933606a4dfe39d9d876e4b916acb6d89e55cc · Passage f1dfade78fefaa8540a2a452a1c1d201bb15d5a795edcd02757fa1a0cc1137fd · Zeichen 13528–13775 im Abschnitt
Wechselwirkungen · Isentress
ISENTRESS 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 33
HOS-119170 · Präparat HOS-094905
famotidine raltegravir AUC ↑ 44%
(raltegravir 400 mg Twice Daily) raltegravir C12 hr ↑ 6%
raltegravir Cmax ↑ 60% No dose adjustment required
for raltegravir (400 mg twice
(increased solubility) daily and 1,200 mg once daily).
gastric pH altering agents: Population PK analysis showed
proton pump inhibitors (e.g. that the effect of gastric pH
omeprazole), H2 blockers (e.g. altering agents on raltegravir
famotidine, ranitidine, cimitedine) pharmacokinetics was minimal
(8.8% decrease in relative
(raltegravir 1,200 mg) bioavailability), and was not
statistically or clinically
significant.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): famotidine (HOS-112087) ranitidine (HOS-085660) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-17T13:16:00Z · SHA-256 6b95e5ffe7a0fcf11532bc18fa0933606a4dfe39d9d876e4b916acb6d89e55cc · Passage 97d9041e14d1760340039cafb1421be56c85012a6d0a1120af6d345f6f984ba8 · Zeichen 19188–20158 im Abschnitt
Wechselwirkungen · Isentress
ISENTRESS 25 mg chewable tablets ISENTRESS 100 mg chewable tablets · Abschnitt 4.5 · PDF-Seite 55
HOS-119222 · Präparat HOS-094905
Co-administration of raltegravir with other agents that increase gastric pH (e.g., omeprazole and
famotidine) may increase the rate of raltegravir absorption and result in increased plasma levels of
raltegravir (see Table 3). Safety profiles in the subgroup of patients in Phase III trials taking proton
pump inhibitors or H2 antagonists were comparable with those who were not taking these antacids.
Therefore, no dose adjustment is required with use of proton pump inhibitors or H2 antagonists.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): famotidine (HOS-112087) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-17T13:16:00Z · SHA-256 6b95e5ffe7a0fcf11532bc18fa0933606a4dfe39d9d876e4b916acb6d89e55cc · Passage e28a7d57ada622ec50b9854d97b7f5a2c051b44b34f824b11029979b6847e0b2 · Zeichen 3917–4413 im Abschnitt
Wechselwirkungen · Isentress
ISENTRESS 25 mg chewable tablets ISENTRESS 100 mg chewable tablets · Abschnitt 4.5 · PDF-Seite 58
HOS-119245 · Präparat HOS-094905
famotidine raltegravir AUC ↑ 44 % No dose adjustment required
(raltegravir 400 mg Twice Daily) raltegravir C12 hr ↑ 6 % for raltegravir.
raltegravir Cmax ↑ 60 %
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): famotidine (HOS-112087)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-17T13:16:00Z · SHA-256 6b95e5ffe7a0fcf11532bc18fa0933606a4dfe39d9d876e4b916acb6d89e55cc · Passage 645dce8ad86b4ac9f3d9793760b699c32cc2dbb856af8a47b580e97c9c89b531 · Zeichen 13553–13803 im Abschnitt
Wechselwirkungen · Isentress
ISENTRESS 100 mg granules for oral suspension · Abschnitt 4.5 · PDF-Seite 79
HOS-119294 · Präparat HOS-094905
Co-administration of raltegravir with other agents that increase gastric pH (e.g., omeprazole and
famotidine) may increase the rate of raltegravir absorption and result in increased plasma levels of
raltegravir (see Table 3). Safety profiles in the subgroup of patients in Phase III trials taking proton
pump inhibitors or H2 antagonists were comparable with those who were not taking these antacids.
Therefore, no dose adjustment is required with use of proton pump inhibitors or H2 antagonists.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): famotidine (HOS-112087) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-17T13:16:00Z · SHA-256 6b95e5ffe7a0fcf11532bc18fa0933606a4dfe39d9d876e4b916acb6d89e55cc · Passage e28a7d57ada622ec50b9854d97b7f5a2c051b44b34f824b11029979b6847e0b2 · Zeichen 3916–4412 im Abschnitt
Wechselwirkungen · Isentress
ISENTRESS 100 mg granules for oral suspension · Abschnitt 4.5 · PDF-Seite 82
HOS-119316 · Präparat HOS-094905
famotidine raltegravir AUC ↑ 44 % No dose adjustment required
(raltegravir 400 mg Twice Daily) raltegravir C12 hr ↑ 6 % for raltegravir.
raltegravir Cmax ↑ 60 %
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): famotidine (HOS-112087)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-17T13:16:00Z · SHA-256 6b95e5ffe7a0fcf11532bc18fa0933606a4dfe39d9d876e4b916acb6d89e55cc · Passage 565a71f27c5e2d46b4fcf6c97dcc3cd511b9ddb0f5fe1153ff12b707f312dd94 · Zeichen 13250–13499 im Abschnitt
Wechselwirkungen · Onglyza
Onglyza 2.5 mg film-coated tablets Onglyza 5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-121463 · Präparat HOS-095365
In in vitro studies, saxagliptin and its major metabolite neither inhibited CYP1A2, 2A6, 2B6, 2C8,
2C9, 2C19, 2D6, 2E1, or 3A4, nor induced CYP1A2, 2B6, 2C9, or 3A4. In studies conducted in
healthy subjects, neither the pharmacokinetics of saxagliptin nor its major metabolite, were
meaningfully altered by metformin, glibenclamide, pioglitazone, digoxin, simvastatin, omeprazole,
antacids or famotidine. In addition, saxagliptin did not meaningfully alter the pharmacokinetics of
metformin, glibenclamide, pioglitazone, digoxin, simvastatin, the active components of a combined
oral contraceptive (ethinyl estradiol and norgestimate), diltiazem or ketoconazole.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288) norgestimate (HOS-110544) ketoconazole (HOS-084513) simvastatin (HOS-086158) famotidine (HOS-112087) digoxin (HOS-086172) ethinyl estradiol (HOS-088135) pioglitazone (HOS-089663) metformin (HOS-091032) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-05-13T16:50:00Z · SHA-256 b9a937f1b60afa9f56d405cc74d388d5177226d03f89a6727bfbd12cd7681944 · Passage 4fbfe941552b68c9f43976ebc2abbc4ef331f7fe3d5539bcf4bea1b37bf371f7 · Zeichen 1541–2203 im Abschnitt
Wechselwirkungen · Komboglyze
Komboglyze 2.5 mg/850 mg film-coated tablets Komboglyze 2.5 mg/1,000 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-213480 · Präparat HOS-155120
The metabolism of saxagliptin is primarily mediated by cytochrome P450 3A4/5 (CYP3A4/5). In in
vitro studies, saxagliptin and its major metabolite neither inhibited CYP1A2, 2A6, 2B6, 2C8, 2C9,
2C19, 2D6, 2E1, or 3A4, nor induced CYP1A2, 2B6, 2C9, or 3A4. In studies conducted in healthy
subjects, neither the pharmacokinetics of saxagliptin nor its major metabolite, were meaningfully
altered by metformin, glibenclamide, pioglitazone, digoxin, simvastatin, omeprazole, antacids or
famotidine. In addition, saxagliptin did not meaningfully alter the pharmacokinetics of metformin,
glibenclamide, pioglitazone, digoxin, simvastatin, the active components of a combined oral
contraceptive (ethinyl estradiol and norgestimate), diltiazem or ketoconazole.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288) norgestimate (HOS-110544) ketoconazole (HOS-084513) simvastatin (HOS-086158) famotidine (HOS-112087) digoxin (HOS-086172) ethinyl estradiol (HOS-088135) pioglitazone (HOS-089663) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-23T16:24:00Z · SHA-256 49284a2aa4bf5d4cc65df4fbea1683957d8ce0be034c6bcc4568504417c45a17 · Passage b48610bb84b0ef0ac38754d2f1349c2cf131d2833d40e888421beab34af131d9 · Zeichen 538–1289 im Abschnitt
Wechselwirkungen · Eliquis
Eliquis 2.5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 12
HOS-124395 · Präparat HOS-095863
No clinically significant pharmacokinetic or pharmacodynamic interactions were observed when
apixaban was coadministered with atenolol or famotidine. Coadministration of apixaban 10 mg with
atenolol 100 mg did not have a clinically relevant effect on the pharmacokinetics of apixaban.
Following administration of the two medicinal products together, mean apixaban AUC and Cmax were
15% and 18% lower than when administered alone. The administration of apixaban 10 mg with
famotidine 40 mg had no effect on apixaban AUC or Cmax.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atenolol (HOS-087794) famotidine (HOS-112087)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-10T16:18:00Z · SHA-256 2c0830820630062f4840bfa3480c75f2e906f4d88046edf420c3e31195b50b2d · Passage 26696b69822ca706aaa12352ae1570f6fb42573c18e6c24bb79ab8ee86ff58b5 · Zeichen 5080–5607 im Abschnitt
Wechselwirkungen · Eliquis
Eliquis 5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 46
HOS-124448 · Präparat HOS-095863
No clinically significant pharmacokinetic or pharmacodynamic interactions were observed when
apixaban was coadministered with atenolol or famotidine. Coadministration of apixaban 10 mg with
atenolol 100 mg did not have a clinically relevant effect on the pharmacokinetics of apixaban.
Following administration of the two medicinal products together, mean apixaban AUC and Cmax were
15% and 18% lower than when administered alone. The administration of apixaban 10 mg with
famotidine 40 mg had no effect on apixaban AUC or Cmax.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atenolol (HOS-087794) famotidine (HOS-112087)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-10T16:18:00Z · SHA-256 2c0830820630062f4840bfa3480c75f2e906f4d88046edf420c3e31195b50b2d · Passage 26696b69822ca706aaa12352ae1570f6fb42573c18e6c24bb79ab8ee86ff58b5 · Zeichen 5064–5591 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.